Prime Medicine wins arbitration against Beam Therapeutics over PM647

Prime Medicine, Inc. (Nasdaq: PRME) announced that an arbitration tribunal ruled in its favor in a dispute with Beam Therapeutics, Inc. over rights to develop its investigational gene editing therapy PM647 for Alpha-1 Antitrypsin Deficiency (AATD).

The tribunal declared that PM647 falls within Prime Medicine's "Field" as defined under a 2019 Collaboration and License Agreement between the two companies, meaning Prime Medicine did not breach the agreement. The company owes no monetary damages to Beam Therapeutics.

PM647 uses a lipid nanoparticle to correct the E342K mutation in the SERPINA1 gene, the most common disease-causing mutation in AATD. In humanized mouse models, the therapy achieved editing efficiency and restored the corrected protein isoform at clinically relevant doses, according to the company.

Prime Medicine plans to submit an investigational new drug application and/or clinical trial application for PM647 in the third quarter of 2026, with initial clinical data expected in 2027.

"We are pleased with the Tribunal's decision, which paves the way for PM647 to advance into the clinic," said Allan Reine, M.D., Chief Executive Officer of Prime Medicine.

AATD is a genetic disorder caused by mutations in the SERPINA1 gene that can lead to lung and liver disease, including cirrhosis and liver failure. There are currently no disease-modifying or curative treatments approved for approximately 200,000 people in the United States and European Union diagnosed with the condition.

You May Also Be Interested In

• Ashland said to explore sale amid takeover interest - Bloomberg
• Syntholene Energy upsizes private placement offering to $2.3M
• Rio Grande Resources plans $2.5M private placement financing